News >

Frontline Pembrolizumab/Chemo Combo Improves PFS in PD-L1+ Metastatic TNBC

Gina Columbus @ginacolumbusonc
Published: Wednesday, Feb 12, 2020

Roger M. Perlmutter, MD, PhD, president, Merck Research Laboratories

Roger M. Perlmutter, MD, PhD

The frontline combination of pembrolizumab (Keytruda) and chemotherapy significantly improved progression-free survival (PFS) compared with chemotherapy alone in patients with metastatic triple-negative breast cancer (TNBC) whose tumors expressed PD-L1 (combined positive score [CPS] ≥10), meeting one of the dual primary endpoints of the phase III KEYNOTE-355 trial (NCT02819518).1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication